Intelligent Bio Solutions Partners with Syrma Johari to Scale Drug Screening Device Production

Reuters2025-12-31
<a href="https://laohu8.com/S/INBS">Intelligent Bio Solutions</a> Partners with Syrma Johari to Scale Drug Screening Device Production

Intelligent Bio Solutions Inc. has announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd., a leading medical device engineering and manufacturing firm. This collaboration aims to scale up the production of Intelligent Bio Solutions’ Intelligent Fingerprinting Drug Screening Reader, with the goal of supporting global expansion and improving long-term margins. The partnership is expected to deliver annual production cost savings of over 40% and enhance gross margins by approximately 20 percentage points compared to previous manufacturing arrangements. Additionally, Syrma Johari’s larger manufacturing capacity will enable Intelligent Bio Solutions to meet growing demand and strengthen its global supply chain ahead of a planned U.S. market entry in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618492) on December 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment